Top

Published in:

01-11-2016 | Review

Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma–a review

Authors: Yijun Luo, Xiaoli Wang, Jinming Yu, Bin Zhang, Minghuan Li

Published in: Tumor Biology | Issue 11/2016

Abstract

Esophageal cancer is one of the most malignant gastrointestinal cancers worldwide. Despite advances in surgical technique, 5-year survival in pathologic stage T2-3N0M0 esophageal squamous cell carcinoma patients who are treated with surgery alone is still poor. The addition of adjuvant radiotherapy may confer a benefit for these patients. However, not all patients could get a benefit from radiotherapy and patients with esophageal squamous cell carcinoma receiving radiotherapy seem to have a disparity in treatment response. Thus, identifying effective prognostic indicator to complement current clinical staging approaches is extremely important. Those prognostic factors could give rise to a novel prognostic stratification system, which serve as criteria for selecting patients for adjuvant therapy. Consequently, it may help to define the subgroups who are more likely to benefit from postoperative radiation therapy.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.CrossRefPubMed

Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Klevebro F, Lindblad M, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014;101(4):321–38. doi:10.1002/bjs.9418.CrossRefPubMed

Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012;92(5):1077–87. doi:10.1016/j.suc.2012.07.008.CrossRefPubMed

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. doi:10.1056/NEJMoa1112088.CrossRefPubMed

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74. doi:10.1245/s10434-011-2049-9.CrossRefPubMed

Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191(2):143–8.CrossRefPubMed

Crosby T, Evans M, Gillies RS, Maynard ND. The management of a patient with an operable carcinoma of the oesophagus. Ann R Coll Surg Engl. 2009;91(5):366–70. doi:10.1308/003588409X432428.CrossRefPubMedPubMedCentral

Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8(6):545–53. doi:10.1016/S1470-2045(07)70172-9.CrossRefPubMed

Schreiber D, Rineer J, Vongtama D, Wortham A, Han P, Schwartz D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol. 2010;5(2):244–50. doi:10.1097/JTO.0b013e3181c5e34f.CrossRefPubMed

10.

Xu Y, Liu J, Du X, Sun X, Zheng Y, Chen J, et al. Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. Radiat Oncol. 2013;8:116. doi:10.1186/1748-717X-8-116.CrossRefPubMedPubMedCentral

11.

Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003;75(2):331–6.CrossRefPubMed

12.

Chen J, Zhu J, Pan J, Zhu K, Zheng X, Chen M, et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann Thorac Surg. 2010;90(2):435–42. doi:10.1016/j.athoracsur.2010.04.002.CrossRefPubMed

13.

Situ D, Wang J, Lin P, Long H, Zhang L, Rong T, et al. Do tumor location and grade affect survival in pT2N0M0 esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2013;146(1):45–51. doi:10.1016/j.jtcvs.2013.01.034.CrossRefPubMed

14.

Martin JT, Worni M, Zwischenberger JB, Gloor B, Pietrobon R, D’Amico TA, et al. The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis. Ann Thorac Surg. 2013;95(2):453–8. doi:10.1016/j.athoracsur.2012.08.049.CrossRefPubMed

15.

Situ D, Wei W, Lin P, Long H, Zhang L, Fu J, et al. Do tumor grade and location affect survival in esophageal squamous cell carcinoma? Survival analysis of 302 cases of pT3N0M0 esophageal squamous cell carcinoma. Ann Surg Oncol. 2013;20(2):580–5. doi:10.1245/s10434-012-2656-0.CrossRefPubMed

16.

Goodner JT. Surgical and radiation treatment of cancer of the thoracic esophagus. Am J Roentgenol Radium Therapy, Nucl Med. 1969;105(3):523–8.CrossRef

17.

Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg. 2012;215(5):643–51. doi:10.1016/j.jamcollsurg.2012.07.006.CrossRefPubMedPubMedCentral

18.

Shridhar R, Weber J, Hoffe SE, Almhanna K, Karl R, Meredith K. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis. J Gastrointest Surg. 2013;17(8):1339–45. doi:10.1007/s11605-013-2192-7.CrossRefPubMed

19.

Mackley HB, Adelstein JS, Reddy CA, Adelstein DJ, Rice TW, Saxton JP, et al. Choice of radiotherapy planning modality influences toxicity in the treatment of locally advanced esophageal cancer. J Gastrointest Cancer. 2008;39(1–4):130–7. doi:10.1007/s12029-009-9067-x.CrossRefPubMed

20.

Li JC, Liu D, Chen MQ, Wang JZ, Chen JQ, Qian FY, et al. Different radiation treatment in esophageal carcinoma: a clinical comparative study. J BUON. 2012;17(3):512–6.PubMed

21.

Chen YJ, Liu A, Han C, Tsai PT, Schultheiss TE, Pezner RD, et al. Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim. 2007;32(3):166–71. doi:10.1016/j.meddos.2006.12.003.CrossRefPubMed

22.

Liu X, Zhang WC, Yu SF, Xiao ZF, Zhou ZM. Patterns of failure after radical surgery among patients with stage T2-3N0M0 esophageal squamous cell carcinoma—potential value of postoperative radiotherapy. Chinese Journal of Radiation Oncology. 2015;24:19–24.

23.

Zhang W, Liu X, Xiao Z, Zhang H, Chen D, Feng Q, et al. Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage III thoracic esophageal squamous cell carcinoma. Oncol Res Treat. 2015;38(3):97–102. doi:10.1159/000375391.CrossRefPubMed

24.

Zhang W, Liu X, Xiao Z, Wang L, Zhang H, Chen D, et al. Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma. Thorac Cancer. 2015;6(5):597–604. doi:10.1111/1759-7714.12228.CrossRefPubMedPubMedCentral

25.

Yang JS, Liu X, Xiao ZF, Liang J, Wang LH, Yin WB, Chen LD. Prospective phase II study of three-dimensional radiotherapy after radical surgery for pT2N0M0 esophageal cancer. Chinese Journal of Radiation Oncology. 2015;28:29–32.

26.

Chen SB, Weng HR, Wang G, Liu DT, Li H, Zhang H, et al. The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2015. doi:10.1007/s00432-015-2041-z.

27.

Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010;139(6):1995–2004.e15. doi:10.1053/j.gastro.2010.05.080.CrossRefPubMed

28.

Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American joint committee on cancer staging system. J Clin Oncol. 2011;29(35):4654–61. doi:10.1200/JCO.2011.38.3174.CrossRefPubMedPubMedCentral

29.

Takeno S, Noguchi T, Takahashi Y, Fumoto S, Shibata T, Kawahara K. Assessment of clinical outcome in patients with esophageal squamous cell carcinoma using TNM classification score and molecular biological classification. Ann Surg Oncol. 2007;14(4):1431–8. doi:10.1245/s10434-006-9286-3.CrossRefPubMed

30.

Xie JJ, Xu LY, Wu ZY, Li LY, Xu XE, Wu JY, et al. Expression of cysteine-rich 61 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2011;37(8):669–74. doi:10.1016/j.ejso.2011.05.009.CrossRefPubMed

31.

Zhao Q, Shen JH, Shen ZY, Wu ZY, Xu XE, Xie JJ, et al. Phosphorylation of fascin decreases the risk of poor survival in patients with esophageal squamous cell carcinoma. J Histochem Cytochem. 2010;58(11):979–88. doi:10.1369/jhc.2010.955765.CrossRefPubMedPubMedCentral

32.

Lee SJ, Lee KS, Yim YJ, Kim TS, Shim YM, Kim K. Recurrence of squamous cell carcinoma of the oesophagus after curative surgery: rates and patterns on imaging studies correlated with tumour location and pathological stage. Clin Radiol. 2005;60(5):547–54. doi:10.1016/j.crad.2004.09.002.CrossRefPubMed

33.

Hou X, Gu YK, Liu XW, Fu JH, Wang X, Zhang LJ, et al. The impact of tumor cell differentiation on survival of patients with resectable esophageal squamous cell carcinomas. Ann Surg Oncol. 2015;22(3):1008–14. doi:10.1245/s10434-014-4067-x.CrossRefPubMed

34.

Yang HX, Hou X, Liu QW, Zhang LJ, Liu JG, Lin P, et al. Tumor location does not impact long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China. Ann Thorac Surg. 2012;93(6):1861–6. doi:10.1016/j.athoracsur.2012.03.002.CrossRefPubMed

35.

Law S, Kwong DL, Kwok KF, Wong KH, Chu KM, Sham JS, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238(3):339–47 . doi:10.1097/01.sla.0000086545.45918.ee.discussion 347-8PubMedPubMedCentral

36.

Li H, Zhang Q, Xu L, Chen Y, Wei Y, Zhou G. Factors predictive of prognosis after esophagectomy for squamous cell cancer. J Thorac Cardiovasc Surg. 2009;137(1):55–9. doi:10.1016/j.jtcvs.2008.05.024.CrossRefPubMed

37.

Ma MQ, Yu ZT, Tang P, Jiang HJ, Zhao XJ, Zhang JG, et al. Is tumor length a prognostic indicator for esophageal squamous cell carcinoma? A single larger study among Chinese patients. Int J Clin Exp Pathol. 2015;8(5):5008–16.PubMedPubMedCentral

38.

Porkholm M, Valanne L, Lonnqvist T, Holm S, Lannering B, Riikonen P, et al. Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2014;61(9):1603–9. doi:10.1002/pbc.25045.CrossRefPubMed

39.

Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.PubMed

40.

Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93(1):107–15. doi:10.1038/sj.bjc.6602625.CrossRefPubMedPubMedCentral

41.

Abedi-Ardekani B, Dar NA, Mir MM, Zargar SA, Lone MM, Martel-Planche G, et al. Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in Central Asia. BMC Cancer. 2012;12:602. doi:10.1186/1471-2407-12-602.CrossRefPubMedPubMedCentral

42.

Zhang W, Zhu H, Liu X, Wang Q, Zhang X, He J, et al. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. Ann Thorac Surg. 2014;98(2):513–9. doi:10.1016/j.athoracsur.2014.03.015.CrossRefPubMed

43.

Gotoh M, Takiuchi H, Kawabe S, Ohta S, Kii T, Kuwakado S, et al. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2007;37(9):652–7. doi:10.1093/jjco/hym089.CrossRefPubMed

44.

Liu XY, Chen G, Wang Z, Liu FY. Clinical significance of detecting mucin 1 mRNA in diagnosing occult lymph node micrometastasis in esophageal cancer patients. Ai Zheng. 2007;26(2):194–9.PubMed

45.

Wang Z, Liu XY, Liu FY, Chen JH. A study of correlation between early postoperative relapse with lymph node micrometastasis in patients with N0 esophageal cancer. Zhonghua Wai Ke Za Zhi. 2004;42(2):68–71.PubMed

46.

Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery. 2000;127(1):40–6. doi:10.1067/msy.2000.102754.CrossRefPubMed

47.

Chen H, Wang Z, Yang Z, Shang B, Liu X, Chen G. Prospective study of adjuvant radiotherapy on preventing lymph node metastasis after Ivor-lewis esophagectomy in esophageal cancer. Ann Surg Oncol. 2013;20(8):2721–6. doi:10.1245/s10434-013-2928-3.CrossRefPubMed

48.

Wang S, Wang Z, Liu X, Yang Y, Shi M, Sun Z. Prognostic significance of Ku80 in pT2N0M0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy. Tumour Biol. 2015;36(8):6181–9. doi:10.1007/s13277-015-3302-9.CrossRefPubMed

49.

Wang S, Wang Z, Yang Z, Liu Y, Liu X, Shang B, et al. Postoperative radiotherapy improves survival in stage pT2N0M0 esophageal squamous cell carcinoma with high risk of poor prognosis. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4622-0.

50.

Zhu H, Bhaijee F, Ishaq N, Pepper DJ, Backus K, Brown AS, et al. Correlation of Notch1, pAKT and nuclear NF-kappaB expression in triple negative breast cancer. Am J Cancer Res. 2013;3(2):230–9.PubMedPubMedCentral

51.

Krikelis D, Bobos M, Karayannopoulou G, Resiga L, Chrysafi S, Samantas E, et al. Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. BMC Clin Pathol. 2013;13:1. doi:10.1186/1472-6890-13-1.CrossRefPubMedPubMedCentral

52.

Cao HH, Zheng CP, Wang SH, Wu JY, Shen JH, Xu XE, et al. A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis. PLoS One. 2014;9(8):e106007. doi:10.1371/journal.pone.0106007.CrossRefPubMedPubMedCentral

53.

Tan H, Zhang H, Xie J, Chen B, Wen C, Guo X, et al. A novel staging model to classify oesophageal squamous cell carcinoma patients in China. Br J Cancer. 2014;110(8):2109–15. doi:10.1038/bjc.2014.101.CrossRefPubMedPubMedCentral

Title: Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma–a review
Authors: Yijun Luo
Xiaoli Wang
Jinming Yu
Bin Zhang
Minghuan Li
Publication date: 01-11-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5373-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression

Emerging tale of UPR and cancer: an essentiality for malignancy

RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer

Dysregulation of TTP and HuR plays an important role in cancers

Natural products against cancer angiogenesis

Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer